ONO 5816
Latest Information Update: 11 Mar 2003
Price :
$50 *
At a glance
- Originator Merck Sante; Ono Pharmaceutical
- Developer Ono Pharmaceutical
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 11 Mar 2003 Discontinued - Phase-II for Diabetes mellitus in Japan (PO)
- 30 Oct 2001 Phase-I clinical trials for Diabetes mellitus in Japan (PO)